Bladder Cancer Trial, Recruiting NCT02379429 Sponsor: National Cancer Institute (NCI) Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT02379429
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with urothelial (bladder/urinary tract) cancer:

  • Adults aged 18 or older who have been diagnosed with, or are suspected to have, urothelial cancer and need some form of medical procedure as part of their diagnosis, treatment, or follow-up care.
  • People who are reasonably well and able to carry out some daily activities (a general health score of 0–3, confirm with trial site).
  • People who are willing and able to give their informed consent to take part.

For healthy volunteers:

  • Adults aged 18 or older who are willing and able to give their informed consent to take part.

Who may not be able to join:

For people with urothelial cancer:

  • People who are currently pregnant.
  • People whose other health conditions mean they cannot safely have a medical procedure, including those currently receiving treatment for another cancer (not counting certain skin cancers).
  • People who have a history of hepatitis B, hepatitis C, or HIV.

For healthy volunteers:

  • People who are currently pregnant.
  • People who have been diagnosed with a cancer that requires treatment, other than minor removal of certain common skin cancers.
  • People with heart, lung, kidney disease, or other significant health conditions (as decided by the lead doctor on the trial).
  • People who have a history of hepatitis B, hepatitis C, or HIV infection.
  • Healthy volunteers who are family members known to carry certain inherited genetic mutations (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Raju R Chelluri, M.D., National Cancer Institute (NCI)

Phone: (240) 858-7481

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 November 2015
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Collect samples for the purpose of studying the molecular mechanisms of carcinogenesis in urothelial cancer.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov